

Certificate of analysis

Product Name/Description: Anti-Human Influenza A (H3N2), Monoclonal (Clone F49)

Cat. #: M146

Lot #: Specified on product label

Storage Conditions: 4 degrees C

Expiration Date: 2 years from date of receipt under proper storage condition

Package Size: 0.1 mg

Package Contents: 1. Anti-Human Influenza A (H3N2), 0.1 mg

Monoclonal (Clone F49)

Note: This product contains bovine serum albumin (BSA). For more information, contact your local office.

Source: Antibody:

Monoclonal antibody was produced from the established hybridoma obtained by fusing the P3U1 myeloma cell line with spleen cells of BALB/c mouse immunized with Influenza A virus A2/Aichi2/68 strain (H3N2 subtype).

The monoclonal antibody was harvested from ascitic fluid.

Quality Control Data:

The lyophilized antibody was dissolved in $50\,\mu l$ of specified water. The antibody dilutions were applied for ELISA assay by colorimetric detection using a microtiter plate immobilized with Influenza Vaccine. The expected

antibody titration was obtained.

Manufacturing Control:

Purification:

Antibody was purified by column chromatography, dissolved in 10 mM PBS, pH 7.4, containing 1.0% bovine

serum albumin, and then lyophilized.

The lyophilized antibody does not contain preservative.

It is certified that this product meets the above specifications, as reviewed and approved by the Quality Department of Takara Bio Inc.



Notice To Purchaser:	
----------------------	--

Please refer to the website.

Product Documents, Patent Markings, Trademarks, & Safety Information:

Refer to website for availability to download or contact your local office: www.takara-bio.co.jp (Japanese) www.takarabio.com (English)

Licence Statements:

Please visit our website and click the "license" button on the product's web page.

©2019 Takara Bio Inc. All Rights Reserved.

All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions.